Birch pollen allergy vaccine tablet - ALK-Abello

Drug Profile

Birch pollen allergy vaccine tablet - ALK-Abello

Alternative Names: Betula Verrucosa allergen extract; Oralgen Birch Pollen; SLIT birch pollen extract; SLITone Birch; SLITonePLUS Birch; SQ tree SLIT-tablet

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ALK-Abello
  • Class Allergens; Antiallergics; Peptide vaccines; Peptides; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic rhinoconjunctivitis

Most Recent Events

  • 14 Sep 2017 ALK-Abello announces intention to submit regulatory applications in the EU and Canada for Allergic rhinoconjunctivitis in 2018
  • 14 Sep 2017 Efficacy and safety data from a phase III trial in Allergic rhinoconjunctivitis released by ALK-Abello
  • 14 Sep 2017 ALK-Abello completes a phase III trial in Allergic rhinoconjunctivitis (In adolescents, In adults) in Sweden, Czech Republic, France, Denmark, Poland, Finland and Germany (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top